Cancer
Credibility 80
Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast Cancer.
November 1, 2026 · American journal of clinical oncology
Key takeaway
A newer drug for triple-negative breast cancer is reaching Black patients at rates similar to white patients. Because this aggressive cancer hits our community hardest, fair access to modern treatments is vital. However, patients in lower-income neighborhoods were less likely to receive it, showing that where you live still affects the care you get.
Why this matters for our communities
Research in cancer helps close long-standing gaps in how Black and African American families are studied, diagnosed, and cared for. Use findings like this one to start informed conversations with your care team — not as a substitute for personal medical advice.
More in Cancer
February 1, 2027Dual-modal immunoassay for prostate cancer-derived exosomes enabled by a black phosphorus/silver SERS substrate and Yb/Er co-doped NaGdF4 UCL nanoprobes.Read December 18, 2026Factors Associated with Screening Mammography Utilization Among Women Veterans in VA Primary Care.Read November 16, 2026Characterizing prior symptomatic emergency department visits among patients undergoing unplanned colon cancer surgery.Read